Loading...

APC anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_APC_040610
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
  • 10Fdot9G2_APC_040610
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
Compare all formats See APC spectral data
Cat # Size Price Save
124311 25 µg ¥15,670
124312 100 µg ¥48,060
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  2. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  3. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  4. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  5. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  6. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  7. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  8. Ngiow S, et al. 2016. Cancer Res . 76: 6266 - 6277. PubMed
  9. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  10. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  11. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  12. Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed
  13. Zhang X, et al. 2023. Heliyon. 9:e13490. PubMed
  14. Tsai KC, et al. 2023. Mar Drugs. 21:. PubMed
  15. Gu T, et al. 2023. Front Immunol. 14:1145028. PubMed
  16. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  17. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  18. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  19. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  20. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  21. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  22. Park S, et al. 2021. Front Immunol. 11:620166. PubMed
  23. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  24. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  25. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  26. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  27. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  28. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  29. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  30. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  31. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  32. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  33. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  34. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  35. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  36. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  37. Zhou KX, et al. 2021. J Immunol Res. 2021:6694392. PubMed
  38. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  39. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  40. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  41. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  42. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  43. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  44. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  45. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  46. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  47. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  48. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  49. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  50. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  51. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  52. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  53. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  54. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  55. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  56. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  57. Almishri W, et al. 2015. J Hepatol. 63: 943-951. PubMed
  58. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
  59. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  60. Shen ZY, et al. 2021. Front Immunol. 12:589200. PubMed
  61. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  62. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  63. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
  64. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  65. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  66. Yi M, et al. 2022. J Hematol Oncol. 15:142. PubMed
  67. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  68. Lindhorst A, et al. 2021. Cell Death Dis. 12:579. PubMed
  69. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  70. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  71. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  72. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  73. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  74. Shen H, et al. 2022. Nat Commun. 13:5013. PubMed
  75. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  76. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  77. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  78. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  79. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
  80. Shaashua L, et al. 2022. Nat Commun. 13:6513. PubMed
  81. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  82. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  83. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  84. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  85. Luo N, et al. 2018. Nat Commun. 0.547222222. PubMed
RRID
AB_10612935 (BioLegend Cat. No. 124311)
AB_10612935 (BioLegend Cat. No. 124312)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
Go To Top Version: 2    Revision Date: 12/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account